
Science in Diabetes
We offer you a 360º view of relevant and trustworthy content in Diabetes.
Science in Infectious Diseases and Vaccines

Differential clinical manifestations and viral load in influenza A(H1N1) pdm09 infections: A comprehensive analysis

Advancements in immunization: Acellular pertussis vaccine and the decline of DTP-related adverse events in Chile

Carriage of Neisseria Meningitidis in Low and Middle Income Countries of the Americas and Asia: A Review of the Literature
Science in Kidney Transplant
We offer you a 360º view of relevant and trustworthy content in Kidney Transplant.

Kidney and Graft Failure Post-Transplant: Reasons and Strategies for Prevention and Management
Disclaimer: The images depicted here are fictitious and meant for illustrative purpose only. Any resemblance to any person, living or dead is purely coincidental.
leave-site-modal-text
You are now being redirected to a third-party website.
Sanofi does not endorse or approve the content, products, services or opinions on the third-party website. Sanofi shall not be responsible or in any way liable for any injury or damage to any persons in view of any reliance placed on or action taken basis of the information on the third party website or any errors, omissions or inaccuracies and/or incompleteness of the information on the third party website.
Patient-Information-Sketch

Option-1
Right answer: Both A and B. As per Diabetic & Ramadan guidelines, T2DM patients can safely continue glargine U-100 once daily at a reduced dose of 15 - 30% at Iftar1,2. Insulin glargine U-100 is safe to be used during Ramadan with no significant increase in hypoglycaemia3. One-on-one dietary educational session can also reduce the number of adverse events of fasting1.
Toujeo-interactive-popup-1

Toujeo-interactive-popup-2

Toujeo-interactive-popup-3

A-single-dose-of-Glulisine-Glargine-video

Basal-plus-regime-Simple-Effective-Low-risk-of-hypoglycemia
